Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Researchers develop therapy to treat the rare skin disease ichthyosis

Drug is ready – but hard to launch: Münster University physicians develop therapy to treat ichthyosis ("fish-scale disease") / No pharmaceutical company found to progress and to market the drug

In the fight against common diseases such as cancer the strategy is clear: scientists are working flat out on research, methods of early detection and treatments. That the demand is enormous is not surprising: according to the Federal Statistics Office, around 26 percent of all deaths in Germany in 2011 were due to cancer. So it is no wonder that patients, researchers and pharmaceutical companies want to see effective drugs developed fast.

But what is the situation with drugs to treat diseases which affect only a few people? “These drugs are often neglected by pharmaceutical companies because they are economically unattractive,” says Dr. Karin Aufenvenne, a biologist, who personally experienced the problem over the past few years. Around one year ago she and Prof. Heiko Traupe, senior physician for dermatology at the skin clinic at Münster University Hospital, achieved a breakthrough in treating a special form of ichthyosis with medication. This highly unpleasant skin disease, often known as fish-scale disease, is caused by genetic defects and occurs directly after birth. Patients suffer from an extreme thickening of the top layer of the skin, which manifests itself in a dark brown, lamellar desquamation covering the entire body. “Around 2,500 people in Europe are estimated to have the disease – which means it is ultra-rare,” says Karin Aufenvenne.

For this reason no pharmaceutical company could be found which was prepared to progress and - above all - market the therapy developed at Münster University (WWU) in close cooperation with the working group headed by Dr. Margitta Dathe at the Leibniz Institute of Molecular Pharmacology (FMP) in Berlin. This situation could, however, change shortly. The reason is that the medication was recently awarded orphan drug status by the European Union – an unprecedented event at WWU and FMP. With the official EU designation as a “drug to treat rare afflictions”, it becomes more economically attractive. “Pharmaceutical companies that buy the rights to such a drug do not have to pay any approval costs, for example,” explains Karin Aufenvenne. “And after regulatory approval they have exclusive rights to the drug for ten years.” In Münster there is a strong desire to find a company attracted by these incentives. “The distress felt by patients who have this disease is enormous – not only due to the physical symptoms, but also because of the mental suffering.”

Get up, have a shower, get dressed and off to work: what for many of us is normal daily life is just not possible for people suffering from ichthyosis. The hornification develops anew every day, which is why those affected with the disease have to bathe thoroughly at least once a day and remove the scales from their body, for example with a pumice stone. To protect the sensitive skin from drying out, patients have to apply a lotion to their whole body several times a day. “Personal hygiene plays a heightened role,” says Karin Aufenvenne, “as the sensitive skin can easily become inflamed, especially in childhood.”
“As a result of the genetic defect,” she explains, “there is an enzyme missing in the body – transglutaminase 1. In the case of healthy people this enzyme acts in the top skin layers. However, if it is missing the natural protective function of the skin is disturbed and the skin loses much more water – which is why scales form over large areas. The substance that we have developed penetrates the skin cells from the outside so that the enzyme can act there.” One of the ways in which the positive effect is shown is through the reduction in the loss of water through the skin. “But the optical effect is also noticeable: the skin normalises itself.”

For people who suffer from ichthyosis, the designation of the therapy developed in Münster as a drug to treat rare afflictions is a ray of hope. The researchers had admittedly already contacted pharmaceutical companies, but as a result of the EU’s designation the situation has improved significantly. There are currently two companies showing a strong interest and negotiations are underway. The Münster scientists are being supported by Clinic Invent, the patents office at the Faculty of Medicine.

Background information: orphan drugs

The term “orphan drug” was first used in 1983 to describe drugs to treat rare diseases. The status of a “drug to treat rare afflictions” is awarded by the EU only if there are fewer than 230,000 patients per year or fewer than five patients for every 10,000 people. Applications are examined by the Committee on Medicines to Treat Rare Diseases, within the European Medicines Agency. If the Committee gives an appropriate recommendation, the EU decides on whether the medicine receives the orphan drug status.

Dr. Christina Heimken | idw
Further information:

More articles from Health and Medicine:

nachricht Advanced analysis of brain structure shape may track progression to Alzheimer's disease
26.10.2016 | Massachusetts General Hospital

nachricht Indian roadside refuse fires produce toxic rainbow
26.10.2016 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel light sources made of 2D materials

Physicists from the University of Würzburg have designed a light source that emits photon pairs. Two-photon sources are particularly well suited for tap-proof data encryption. The experiment's key ingredients: a semiconductor crystal and some sticky tape.

So-called monolayers are at the heart of the research activities. These "super materials" (as the prestigious science magazine "Nature" puts it) have been...

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Prototype device for measuring graphene-based electromagnetic radiation created

28.10.2016 | Power and Electrical Engineering

Gamma ray camera offers new view on ultra-high energy electrons in plasma

28.10.2016 | Physics and Astronomy

When fat cells change their colour

28.10.2016 | Life Sciences

More VideoLinks >>>